UNSPSC 51382404: Bromfenac sodium hydrate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H11BrNO3.2Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ECV571Y37, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate, but more generally known as bromfenac sodium hydrate, which bears US NIH Compound Identifier 11954316.

European Medicines Agency schedules bromfenac sodium hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05913MIG. Most nations, for tariff purposes, schedule bromfenac sodium hydrate under HS 29225000. SMILES: C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].O.O.O.[NA+].[NA+].

UNSPSC 51382404 Bromfenac sodium hydrate is a Commodity code that nominally covers a specific nonsteroidal anti-inflammatory ophthalmic agent, but recent state and local opportunities tagged under this code show little alignment with the pharmaceutical substance itself. The three most recent solicitations involve naloxone and drug deactivation systems (Seminole County, Florida), a direct-to-manufacturer prescription program pilot (Texas HHS), and a multistate cooperative purchasing contract for generic pharmaceuticals and OTC products (Minnesota). The Seminole County procurement is the only opportunity with direct product procurement, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding. The issuing bodies include county health departments, state health agencies, and multistate cooperative purchasing alliances; no vendor consolidation or repeat buyers emerge from the recent record. Geographic activity spans Florida, Texas, and Minnesota, with the MMCAP contract extending to Oregon through cooperative purchasing.

The Seminole County IFB (IFB60459723LAS) closed July 26, 2023, and required quarterly deliveries to the Community Health Building in Sanford with all shipping costs included in vendor bids; the contract carried a two-year initial term with a one-year renewal option and included FEMA compliance requirements. The Texas HHS RFI (HHS0017013) issued April 3, 2026, was exploratory in scope, seeking vendor capabilities for direct-to-manufacturer prescription contracting outside traditional PBM and GPO channels; no award value or formal evaluation criteria were specified. The MMCAP RFP (S1070000015802) closed March 26, 2026, and sought generic pharmaceutical and OTC products from manufacturers through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with contract effectiveness July 1, 2026, and pricing weighted at 75 percent of evaluation criteria; vendors faced a 3 percent administrative fee and performance penalties of $200 to $1,500 per violation. The code shows limited relevance to bromfenac sodium hydrate specifically; opportunities are tagged broadly across pharmaceutical procurement rather than specialty ophthalmic agents.